Bremelanotide

The International Nonproprietary Name (INN) for PT-141. FDA-approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. A melanocortin receptor agonist (MC3R and MC4R) that acts centrally through the nervous system rather than peripherally on vascular tissue, distinguishing it mechanistically from PDE5 inhibitors.